Takeda's Entyvio gets FDA nod in ulcerative colitis, Crohn's disease
By Jennifer Boggs
Tuesday, May 20, 2014
Coming as little surprise after an FDA advisory panel backed Entyvio (vedolizumab) for treatment of severe ulcerative colitis and moderate to severe Crohn's disease, Takeda Pharmaceutical Co. Ltd.'s drug gained approval on its May 20 PDUFA date, becoming the first integrin inhibitor to hit the market since Biogen Idec Inc.'s Tysabri (natalizumab).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.